Commentary on "Vascular cognitive impairment: Today and tomorrow"

Alzheimer's and Dementia

Volumn 2, Issue 3, 2006, Pages 195-197

  Kuller, Lewis H ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HUMAN; HYPERTENSION; MULTIINFARCT DEMENTIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 33744906291     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2006.03.014     Document Type: Note

References (32)

1. Chui H.C., Victoroff J.I.M.B., Margolin D., Jagust W., Shankle R., and Katzman R. Criteria for the diagnosis of ischemic VaD proposed by the state of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 42 (1992) 473-480
2. Kuller L.H., Lopez O.L., Jagust W.J., Becker J.T., DeKosky S.T., Lyketsos C., et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology 64 (2005) 1548-1552
3. Liao D., Cooper L., Cai J., Toole J., Bryan N., Burke G., et al. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors. the ARIC study. Neuroepidemiology 16 (1997) 149-162
4. Breteler M.M., van Swieten J.C., Bots M.L., Grobbee D.E., Claus J.J., van den Hout J.H., et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study. the Rotterdam Study. Neurology 44 (1994) 1246-1252
5. Launer L.J., Berger K., Breteler M.M.B., Dufouil C., Fuhrer R., Giampaoli S., et al. Regional variability in the prevalence of cerebral white matter lesions. An MRI study in 9 European countries (CASCADE). Neuroepidemiology 26 (2006) 23-29
6. DeCarli C., Massaro J., Harvey D., Hald J., Tullberg M., Au R., et al. Measures of brain morphology and infarction in the Framingham heart study. establishing what is normal. Neurobiol Aging 26 (2005) 491-510
7. Longstreth Jr. W.T., Arnold A.M., Beauchamp Jr. N.J., Manolio T.A., Lefowitz D., Jungreis C., et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly. The Cardiovascular Health Study. Stroke 36 (2005) 56-61
8. Starr J.M., Leaper S.A., Murray A.D., Lemmon H.A., Staff R.T., Deary I.J., et al. Brain white matter lesions detected by magnetic resonance imaging are associated with balance and gait speed. J Neurol Neurosurg Psychiatry 74 (2003) 94-98
9. Vermeer S.E., Hollander M., van Dijk E.J., Hofman A., Koudstaal P.J., and Breteler M.M.B. Silent brain infarcts and white matter lesions increase stroke risk in the general population. The Rotterdam Scan Study. Stroke 34 (2003) 1126-1129
10. Kuller L.H., Longstreth Jr. W.T., Arnold A.M., Bernick C., Bryan R.N., Beauchamp Jr. N.J., and Cardiovascular Health Study Collaborative Research Group. White matter hyperintensity on cranial magnetic resonance imaging. A predictor of stroke. Stroke 34 (2004) 1821-1825
11. th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, March 2-5, 2006, Phoenix, AZ.
12. Vermeer S.E., Prins N.D., Den Heijer T., Hofman A., Koudstaal P.J., and Breteler M.M.B. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348 (2003) 1215-1222
13. Gold G., Kovari E., Herrman F.R., Canuto A., Hof P.R., Michel J.-P., et al. Cognitive consequences of thalamic, basal ganglia, and deep white matter lacunes in brain aging and dementia. Stroke 36 (2005) 1184-1188
14. Longstreth Jr. W.T. Brain vascular disease overt and covert (editorial). Stroke 36 (2005) 2062-2063
15. White L., Petrovitch H., Hardman J., Nelson J., Davis D.J., Ross W., et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann NY Acad Sci (2002) 977-1023
16. van der Flier W.M., van Straaten E.C.W., Barkhof F., Verdelho A., Madureira S., Pantoni L., et al. Small vessel disease and general cognitive function in nondisabled elderly. The LADIS study. Stroke 36 (2005) 2116-2120
17. O'Rourke M.F., and Safar M.E. Relationship between aortic stiffening and microvascular disease in brain and kidney. Cause and logic of therapy. Hypertension 46 (2005) 200-204
18. Peila R., White L.R., Petrovich H., Masaki K., Ross G.W., Havlik R.J., et al. Joint effect of the Apo E gene and midlife systolic blood pressure on late-life cognitive impairment. The Honolulu-Asia Aging Study. Stroke 32 (2001) 2882-2889
19. Launer L.J., Masaki K., Petrovitch H., Foley D., and Havlik R.J. The association between midlife blood pressure levels and late-life cognitive function. JAMA 274 (1995) 1846-1851
20. Elias M.F., D'Agostino R.B., Elias P.K., and Wolf P.A. Neuropsychological test performance, cognitive functioning, blood pressure, and age. The Framingham Study. Exp Aging Res 21 (1995) 369-391
21. Elias P.K., Elias M.F., D'Agostino R.B., Cupples L.A., Wilson P.W., Silbershatz H., et al. NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 20 (1997) 1388-1395
22. Gorelick P.B., and William M. Feinberg Lecture. Cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke 36 (2005) 875-879
23. Forette F., Seux M.L., Staessen J.A., Thijs L., Babarskiene M.R., Babeanu S., et al., Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment. New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162 (2002) 2046-2052
24. Schiffrin E.L. Blood pressure lowering in PROGRESS (Perindopril Protection Against Recurrent Stroke Study) and white matter hyperintensities. Should this progress matter to patients?. Circulation 112 (2005) 1525-1526
25. Schmidt R., Ropele S., Enzinger C., Petrovic K., Smith S., Schmidt H., et al. White matter lesion progression, brain atrophy, and cognitive decline. The Austrian Stroke Prevention Study. Ann Neurol 58 (2005) 610-616
26. Dufouil C., Chalmers J., Coskun O., Besancon V., Bousser M.-G., Guillon P., et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke. The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) magnetic resonance imaging substudy. Circulation 112 (2005) 1644-1650
27. Gueyffier F., Boutitie F., Boissel J.P., Pocock S., Coope J., Cutler J., et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med 126 (1997) 761-767
28. Kuller L., and Reisler D.M. An explanation for variations in distribution of stroke and arteriosclerotic heart disease among populations and racial groups. Am J Epidemiol 93; (1971) 1-9
29. Carmelli D., DeCarli C., Swan G.E., Jack L.M., Reed T., Wolf P.A., et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 29 (1998) 1177-1181
30. Atwood L.D., Wolf P.A., Heard-Costa N.L., Massaro J.M., Beiser A., D'Agostino R.B., et al. Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke 35 (2004) 1609-1613
31. Fazekas F., Schmidt R., and Scheltens P. Pathophysiologic mechanisms in the development of age-related white matter changes of the brain. Dement Geriatr Cogn Disord 9 (1998) 2-5
32. The National Heart, Lung, and Blood Institute Working Group on Future Directions in Hypertension Treatment Trials. Major clinical trials of hypertension. What should be done next?. Hypertension 46 (2005) 1-6